ES2384973T3 - Un casete y vector de expresión para la expresión transitoria o estable de moléculas exógenas - Google Patents

Un casete y vector de expresión para la expresión transitoria o estable de moléculas exógenas Download PDF

Info

Publication number
ES2384973T3
ES2384973T3 ES04711259T ES04711259T ES2384973T3 ES 2384973 T3 ES2384973 T3 ES 2384973T3 ES 04711259 T ES04711259 T ES 04711259T ES 04711259 T ES04711259 T ES 04711259T ES 2384973 T3 ES2384973 T3 ES 2384973T3
Authority
ES
Spain
Prior art keywords
expression cassette
seq
sequence
vector
nucleotide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES04711259T
Other languages
English (en)
Spanish (es)
Inventor
William P. Sisk
Holly Prentice
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biogen Inc
Biogen MA Inc
Original Assignee
Biogen Idec Inc
Biogen Idec MA Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen Idec Inc, Biogen Idec MA Inc filed Critical Biogen Idec Inc
Application granted granted Critical
Publication of ES2384973T3 publication Critical patent/ES2384973T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/42—Vector systems having a special element relevant for transcription being an intron or intervening sequence for splicing and/or stability of RNA

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Biochemistry (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Sampling And Sample Adjustment (AREA)
  • Crystals, And After-Treatments Of Crystals (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Tents Or Canopies (AREA)
  • Paints Or Removers (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
ES04711259T 2003-02-14 2004-02-13 Un casete y vector de expresión para la expresión transitoria o estable de moléculas exógenas Expired - Lifetime ES2384973T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US44817903P 2003-02-14 2003-02-14
US448179P 2003-02-14
PCT/US2004/004407 WO2004074439A2 (en) 2003-02-14 2004-02-13 An expression cassette and vector for transient or stable expression of exogenous molecules

Publications (1)

Publication Number Publication Date
ES2384973T3 true ES2384973T3 (es) 2012-07-16

Family

ID=32908549

Family Applications (1)

Application Number Title Priority Date Filing Date
ES04711259T Expired - Lifetime ES2384973T3 (es) 2003-02-14 2004-02-13 Un casete y vector de expresión para la expresión transitoria o estable de moléculas exógenas

Country Status (21)

Country Link
US (2) US7494805B2 (cg-RX-API-DMAC7.html)
EP (1) EP1594955B1 (cg-RX-API-DMAC7.html)
JP (2) JP2006517802A (cg-RX-API-DMAC7.html)
KR (1) KR20050101554A (cg-RX-API-DMAC7.html)
CN (1) CN1774500B (cg-RX-API-DMAC7.html)
AT (1) ATE553185T1 (cg-RX-API-DMAC7.html)
AU (1) AU2004213797B2 (cg-RX-API-DMAC7.html)
BR (1) BRPI0407487A (cg-RX-API-DMAC7.html)
CA (1) CA2515481A1 (cg-RX-API-DMAC7.html)
DK (1) DK1594955T3 (cg-RX-API-DMAC7.html)
EA (2) EA008439B1 (cg-RX-API-DMAC7.html)
ES (1) ES2384973T3 (cg-RX-API-DMAC7.html)
IL (1) IL170178A (cg-RX-API-DMAC7.html)
IS (1) IS7974A (cg-RX-API-DMAC7.html)
MX (1) MXPA05008523A (cg-RX-API-DMAC7.html)
NO (1) NO20054202L (cg-RX-API-DMAC7.html)
NZ (1) NZ542316A (cg-RX-API-DMAC7.html)
PL (1) PL378110A1 (cg-RX-API-DMAC7.html)
RS (1) RS20050614A (cg-RX-API-DMAC7.html)
WO (1) WO2004074439A2 (cg-RX-API-DMAC7.html)
ZA (1) ZA200506413B (cg-RX-API-DMAC7.html)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL378110A1 (pl) 2003-02-14 2006-03-06 Biogen Idec Ma Inc. Kaseta ekspresyjna i wektor do przejściowej albo stabilnej ekspresji egzogennych cząsteczek
UA87467C2 (xx) 2003-09-19 2009-07-27 Янссен Фармацевтика Н.В 4-((феноксіалкіл)тіо)феноксіоцтова кислота та її аналоги$4-((феноксиалкил)тио)феноксиуксусная кислота и ее аналоги
BRPI0415446A (pt) * 2003-10-14 2006-12-05 Biogen Idec Inc recombinação mediada por flp
EP1733034A4 (en) * 2004-03-15 2010-01-20 Biogen Idec Inc METHOD AND CONSTRUCTS FOR THE EXPRESSION OF POLYPEPTIDE MULTIMERS IN EUKARYONTIC CELLS USING ALTERNATIVE SPLEISSEN
MY147518A (en) 2004-09-15 2012-12-31 Janssen Pharmaceutica Nv 4-((phenoxyalkyl)thio)-phenoxyacetic acids and analogs
JO3006B1 (ar) 2005-09-14 2016-09-05 Janssen Pharmaceutica Nv املاح ليسين مبتكرة من مشتقات حامض 4-((فينوكسي الكيل)ثيو) فينوكسي الخليك
GB0606190D0 (en) 2006-03-28 2006-05-10 Isis Innovation Construct
PE20080188A1 (es) 2006-04-18 2008-03-10 Janssen Pharmaceutica Nv Derivados del acido benzoazepin-oxi-acetico como agonistas de ppar-delta usados para aumentar hdl-c, reducir ldl-c y reducir colesterol
CN101535338A (zh) * 2006-10-18 2009-09-16 斯克利普斯研究院 在哺乳动物细胞中将非天然氨基酸遗传掺入蛋白质
WO2011017319A1 (en) 2009-08-03 2011-02-10 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Methods of treating disorders associated with protein polymerization
US9072772B2 (en) 2009-11-05 2015-07-07 University of Pittsburgh—of the Commonwealth System of Higher Education Methods of treating disorders associated with protein aggregation
US8809617B2 (en) * 2009-11-05 2014-08-19 The University of Pittsburgh—Of the Commonwealth System of Higher Education Automated high-content live animal drug screening using C. elegans
MX2012006884A (es) * 2009-12-21 2012-07-04 Sanofi Sa Anmal transgenico no humano y sus usos.
UY33126A (es) * 2009-12-21 2011-07-29 Sanofi Sa Animal transgénico no humano y sus usos
US8993316B2 (en) 2011-11-16 2015-03-31 Brian P. Hanley Methods and compositions for gene therapy and GHRH therapy
WO2013158664A2 (en) 2012-04-17 2013-10-24 Kythera Biopharmaceuticals, Inc. Use of engineered viruses to specifically kill senescent cells
US9816102B2 (en) 2012-09-13 2017-11-14 Indiana University Research And Technology Corporation Compositions and systems for conferring disease resistance in plants and methods of use thereof
BR122020023058B1 (pt) 2012-12-10 2023-12-05 Biogen Ma Inc Ácido nucleico isolado ou ácidos nucleicos
MX2015013842A (es) * 2013-03-30 2017-01-23 Usha Biotech Ltd Metodos y constructos para expresar proteinas biologicamente activas en celulas de mamifero.
WO2015162930A1 (ja) * 2014-04-24 2015-10-29 一般社団法人 医療産業イノベーション機構 タンパク質発現を向上させる方法およびタンパク質発現用組成物
TWI747098B (zh) 2018-12-21 2021-11-21 美商美國禮來大藥廠 抗angptl3/8複合物抗體及其使用方法
US11415263B2 (en) * 2020-03-20 2022-08-16 Edwards Vacuum Llc Conversion kit for a support frame, a support frame and an integrated vacuum system mounted in a support frame

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8717430D0 (en) 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
DK0897983T3 (da) 1991-10-25 2003-08-11 Immunex Corp Antistoffer mod CD40-L
ES2187505T3 (es) 1992-04-02 2003-06-16 Sembiosys Genetics Inc Elementos cis de proteinas de cuerpo oleoso como señales reguladoras.
AU698739B2 (en) 1995-06-06 1998-11-05 Isis Pharmaceuticals, Inc. Oligonucleotides having phosphorothioate linkages of high chiral purity
NZ311335A (en) 1995-06-07 1998-05-27 Immunex Corp Cd40l muteins and their use as ligands
US5985662A (en) 1995-07-13 1999-11-16 Isis Pharmaceuticals Inc. Antisense inhibition of hepatitis B virus replication
US6087129A (en) * 1996-01-19 2000-07-11 Betagene, Inc. Recombinant expression of proteins from secretory cell lines
US6448389B1 (en) * 1996-04-23 2002-09-10 The Wistar Institute Of Anatomy And Biology Human cytomegalovirus DNA constructs and uses therefor
CA2297375A1 (en) * 1997-07-24 1999-02-04 Valentis, Inc. Ghrh expression system and methods of use
EP1047774A1 (en) * 1998-01-16 2000-11-02 California Pacific Medical Center Research Institute Methods and compositions for gene delivery
US6455677B1 (en) * 1998-04-30 2002-09-24 Boehringer Ingelheim International Gmbh FAPα-specific antibody with improved producibility
EP0953639A1 (en) * 1998-04-30 1999-11-03 Boehringer Ingelheim International GmbH FAPalpha-specific antibody with improved producibility
CA2329259C (en) * 1998-05-27 2003-08-05 Avigen, Inc. Convection-enhanced delivery of aav vectors
EP1092768A1 (en) * 1999-10-16 2001-04-18 ARTEMIS Pharmaceuticals GmbH Conditional gene trapping construct for the disruption of genes
WO2001094599A1 (en) 2000-06-07 2001-12-13 Smittskyddsinstitutet Gene expression cassette and its use
AU7061401A (en) 2000-07-05 2002-01-14 Transgene Sa Chimeric promoters for controlling expression in smooth muscle cells
JP2002233374A (ja) * 2001-02-06 2002-08-20 Japan Science & Technology Corp 遺伝子導入及び/又は遺伝子欠損非ヒト動物作製用ベクター
DE10133407A1 (de) 2001-07-13 2003-01-23 Basf Ag Expressionskassetten zur transgenen Expression von Nukleinsäuren
US20030235823A1 (en) * 2002-06-24 2003-12-25 The University Of Alabama Nucleotide sequences that code for torsin genes, torsin proteins, and methods of using the same to treat protein-aggregation
PL378110A1 (pl) * 2003-02-14 2006-03-06 Biogen Idec Ma Inc. Kaseta ekspresyjna i wektor do przejściowej albo stabilnej ekspresji egzogennych cząsteczek

Also Published As

Publication number Publication date
EA200501296A1 (ru) 2006-04-28
NZ542316A (en) 2006-04-28
IL170178A (en) 2011-12-29
JP2010213718A (ja) 2010-09-30
NO20054202L (no) 2005-11-11
NO20054202D0 (no) 2005-09-09
AU2004213797A1 (en) 2004-09-02
US20060141625A1 (en) 2006-06-29
CA2515481A1 (en) 2004-09-02
EA008439B1 (ru) 2007-06-29
EP1594955A2 (en) 2005-11-16
AU2004213797B2 (en) 2009-09-17
RS20050614A (sr) 2007-12-31
CN1774500B (zh) 2011-03-02
BRPI0407487A (pt) 2006-02-14
EP1594955A4 (en) 2006-07-19
WO2004074439A2 (en) 2004-09-02
PL378110A1 (pl) 2006-03-06
MXPA05008523A (es) 2005-10-20
WO2004074439A9 (en) 2004-12-23
US7494805B2 (en) 2009-02-24
HK1084690A1 (en) 2006-08-04
IS7974A (is) 2005-08-11
ATE553185T1 (de) 2012-04-15
DK1594955T3 (da) 2012-06-25
US20100158879A1 (en) 2010-06-24
EA200700469A1 (ru) 2008-10-30
WO2004074439A3 (en) 2004-10-28
KR20050101554A (ko) 2005-10-24
JP2006517802A (ja) 2006-08-03
CN1774500A (zh) 2006-05-17
ZA200506413B (en) 2006-04-26
EP1594955B1 (en) 2012-04-11

Similar Documents

Publication Publication Date Title
US20100158879A1 (en) Expression cassette and vector for transient or stable expression of exogenous molecules
JP7472121B2 (ja) アルブミン遺伝子座からの導入遺伝子発現のための組成物及び方法
JP7578590B2 (ja) 第ix因子を発現するための組成物及び方法
JP2006517802A5 (cg-RX-API-DMAC7.html)
ES2151463T3 (es) Constructos de adn para la activacion y la modificacion de la expresion de genes endogenos.
CA2160034C (en) Gibbon ape leukemia virus-based retroviral vectors
US20030003583A1 (en) Regulation of transgene expression following AAV transduction
US20250281646A1 (en) Plasmid dna constructs for therapeutic protein expression
CN1265144A (zh) 鉴定可用于通过内源基因激活生产人蛋白质的人细胞系
KR102937659B1 (ko) 강화된 발현 시스템 및 그 사용방법
EP0771874B1 (en) Transgenic protein production
ES2214474T3 (es) Aumento de la expresion mediante orientacion genica en secuencias endogenas de tipo retrovirus.
CA3255217A1 (en) CONTAINER INTENDED FOR A SUBSTANCE
HK1084690B (en) An expression cassette and vector for transient or stable expression of exogenous molecules
JP2003325188A (ja) サイトカイン遺伝子組換えカイコおよびそのタンパク質の製造方法
US20070134795A1 (en) Flp-mediated recombination
Waldbieser et al. Tissue-specific expression of the human neuropeptide Y gene in transgenic mice
KR20200030468A (ko) 핫스팟 내에 목적 단백질의 암호화 코딩 유전자가 삽입된 재조합 세포, 이의 제조 방법 및 이의 용도
KR20090028681A (ko) 당화된 g-csf
US20050064547A1 (en) Vectors and transfected cells